Phase 1 dose-escalation study of BI 836909, an anti-BCMA bi-specific T-cell engager, in relapsed and/or refractory multiple myeloma (RRMM).
暂无分享,去创建一个
H. Einsele | P. Moreau | C. Langer | G. Zugmaier | T. Facon | M. Attal | C. Gomez-Roca | G. Munzert | M. Topp | E. Gracien | B. Hébraud | J. Düll